Determining Risk Factors for Recurrence of Primary Localized Cutaneous Melanoma
Researchers sought to determine the risk of disease recurrence in patients with localized melanoma at high risk of disease metastasis.
Melanoma
Machine Versus Physician: Assigning Diagnoses to Pigmented Skin Lesions
Approximately one half of all biopsied/excised lesions from patients who have sun-damaged skin are nonmelanocytic.
Lack of Confidence in Undertaking Skin Self-Examinations in Patients With Melanoma
Efforts to integrate new digital technologies to increase regular and thorough skin self-examination for patients with melanoma are warranted, provided sufficient technical support is provided.
Time Between Initial Surgery and First Distant Recurrence Not Predictive of Response to Systemic Therapy in Metastatic Melanoma
With the exception of those enrolled in a clinical trial, all patients in this study received systemic monotherapy as first-line treatment of metastatic melanoma.
Melanoma Treatment Regimens
View treatment regimens for melanoma, including guidance on options and dosing for a number of drugs including ipilimumab and dacarbazine.
Do Different Risk Factors Influence the Route of Melanoma Metastasis?
Risk factors for melanoma metastasis differ depending on whether the route is through the lymphatic system or the blood. These findings were published in JAMA Dermatology.1 Cutaneous melanoma is widely thought to spread through both lymphatic and hematogenous routes. The former route is believed to involve locoregional disease spread to skin and lymph nodes whereas…
The Role of Metastasectomy for Melanoma Reexamined in the Modern Era
In the modern era of therapeutic agents, metastasectomy was still associated with improved survival outcomes for patients with stage IV melanoma.
Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Depth of Response to TKIs, Immunotherapies Correlates to Longer PFS and OS
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Next post in Melanoma
